- Home
- FWRG vs ARDX Comparison
FWRG vs ARDX Comparison
Compare FWRG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- ARDX
- Stock Information
- Founded
- FWRG 1983
- ARDX 2007
- Country
- FWRG United States
- ARDX United States
- Employees
- FWRG N/A
- ARDX N/A
- Industry
- FWRG Restaurants
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- ARDX Health Care
- Exchange
- FWRG Nasdaq
- ARDX Nasdaq
- Market Cap
- FWRG 970.4M
- ARDX 882.9M
- IPO Year
- FWRG 2021
- ARDX 2014
- Fundamental
- Price
- FWRG $17.66
- ARDX $5.21
- Analyst Decision
- FWRG Strong Buy
- ARDX Strong Buy
- Analyst Count
- FWRG 10
- ARDX 9
- Target Price
- FWRG $22.20
- ARDX $10.50
- AVG Volume (30 Days)
- FWRG 1.1M
- ARDX 4.5M
- Earning Date
- FWRG 08-05-2025
- ARDX 08-04-2025
- Dividend Yield
- FWRG N/A
- ARDX N/A
- EPS Growth
- FWRG N/A
- ARDX N/A
- EPS
- FWRG 0.06
- ARDX N/A
- Revenue
- FWRG $1,105,027,000.00
- ARDX $386,146,000.00
- Revenue This Year
- FWRG $21.66
- ARDX $10.10
- Revenue Next Year
- FWRG $16.02
- ARDX $32.38
- P/E Ratio
- FWRG $297.74
- ARDX N/A
- Revenue Growth
- FWRG 14.53
- ARDX 83.88
- 52 Week Low
- FWRG $12.90
- ARDX $3.21
- 52 Week High
- FWRG $22.71
- ARDX $7.18
- Technical
- Relative Strength Index (RSI)
- FWRG 53.06
- ARDX 73.28
- Support Level
- FWRG $16.04
- ARDX $4.08
- Resistance Level
- FWRG $19.50
- ARDX $5.31
- Average True Range (ATR)
- FWRG 1.01
- ARDX 0.21
- MACD
- FWRG 0.03
- ARDX 0.08
- Stochastic Oscillator
- FWRG 46.82
- ARDX 80.21
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.